Stock Events

Neurocrine Biosciences 

$149
96
+$1.37+0.93% Today

Statistics

Day High
150.06
Day Low
148.23
52W High
-
52W Low
-
Volume
110.51
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.79
-0.01
0.76
1.54
Expected EPS
1.07
Actual EPS
1.2

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0K6R.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie competes in the neurology and psychiatry market, particularly with treatments for Parkinson's disease, directly competing with Neurocrine's offerings.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.57B
Teva Pharmaceutical has a strong focus on CNS (Central Nervous System) disorders, including treatments for movement disorders, making it a direct competitor.
Sage Therapeutics
SAGE
Mkt Cap707.74M
Sage Therapeutics focuses on CNS disorders, including treatments for depression and movement disorders, areas where Neurocrine also operates.
Acadia Pharmaceuticals
ACAD
Mkt Cap2.94B
Acadia Pharmaceuticals offers products for CNS disorders, including Parkinson’s disease psychosis, competing in Neurocrine's market space.
Alkermes
ALKS
Mkt Cap3.99B
Alkermes competes in the area of CNS disorders, with a focus on schizophrenia and bipolar disorder, overlapping with Neurocrine's psychiatric disorder treatments.
AMGEN
AMGN
Mkt Cap177.47B
Amgen has a broad portfolio that includes treatments for neurological disorders, potentially competing with Neurocrine's neurology-focused therapies.
Biogen
BIIB
Mkt Cap33.5B
Biogen focuses on neurology, with treatments for multiple sclerosis and spinal muscular atrophy, indicating a competitive overlap in the neurology space.
Luna Innovations
LUNA
Mkt Cap100.52M
Lundbeck specializes in psychiatric and neurological disorders, including treatments for depression and Parkinson’s, competing with Neurocrine's portfolio.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., Inc. has a diversified portfolio that includes treatments for neurological conditions, potentially competing with Neurocrine.
Pfizer
PFE
Mkt Cap163.88B
Pfizer has a broad range of treatments, including for neurological conditions, making it a competitor in the neurology and psychiatry market.

About

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Kevin C. Gorman Ph.D.
Employees
1150
Country
United States
ISIN
US64125C1099
WKN
000900964

Listings